loader image
Friday, June 27, 2025
77.1 F
McAllen
We Welcome your Press Release
- Advertisement -

Use Of Anticoagulant Drug After Aortic Valve Replacement Lowers Mortality Risk

Translate to Spanish or other 102 languages!

 Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings. Image for illustration purposes
 Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings. Image for illustration purposes
- Advertisement -

By Mayo Clinic

Newswise — ROCHESTER, Minn. — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

The use of bioprosthetic aortic valve replacement has increased significantly during the past decade. Among its advantages is that most patients can avoid warfarin for anticoagulation treatment. Even so, research has been conflicting on whether patients would benefit from more aggressive early postoperative anticoagulation treatment.

- Advertisement -

Mayo Clinic researchers analyzed nationwide data on more than 10,000 patients who underwent bioprosthetic aortic valve replacement. Warfarin use was associated with a 32% reduction in mortality risk. Patients treated with warfarin early postoperatively also had an increased risk of major bleeding events.

“The findings support early warfarin use in appropriately selected patients, such as patients with low bleeding risk,” says Hartzell Schaff, M.D., a Mayo Clinic cardiovascular surgeon who contributed to the study. “There’s often reluctance to prescribe anticoagulant treatment early after surgery due to concerns about bleeding and uncertainty about benefits. Our research finds that the small increased hazard of bleeding (4% versus 2.3%) may be an acceptable risk given the benefits in terms of mortality risk as well as reduced risk of thromboembolism.”

The Mayo Clinic study analyzed deidentified patient data from 2007 to 2019 using OptumLabs Data Warehouse, which contains claims data of commercially insured and Medicare Advantage enrollees of all ages and races throughout the U.S.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Becomes RGV’s First and Only Comprehensive Multiple Sclerosis Center

Mega Doctor News EDINBURG, Texas - DHR Health is proud to announce that...

Breaking the Silence About Men Breaking Bones

Mega Doctor News By Ohio State University Wexner Medical Center  Newswise — COLUMBUS, Ohio –...

What to Know About Alzheimer’s Disease

Mega Doctor News Medical News Today Alzheimer’s disease is a progressive condition that...

Gearing Up for Giving: From Classrooms to Communities, Annual Back-to-School Drive in Full Effect

Mega Doctor News Texas Border Business Rio Grande Valley/San Antonio, TX - Lone Star...
- Advertisement -
×